Gyre Therapeutics News and Activities

Gyre Therapeutics is owned by GNI.

GNI is a company listed under the stock ticker 2160 (JP).

GNI has a direct presence in 2 countries.

GNI has 3 subsidiaries including Cullgen, Gyre Therapeutics and Micren Healthcare.

They are in:

• Biotechnology75%
• Business Services25%

Acquisition, funding and merger involving GNI.

• GNI has announced the acquisition of Ayumi Pharmaceutical  (posted on June 12 2026).

View the org chart displaying its 23 main executives

Most searched biographies at Gyre Therapeutics

• Ying Luo, Chairman of the Board and Chief Executive Officer
• Rodney Nussbaum, Director
• Renate Parry, Board Member

Create your alert
to follow the executive moves at Gyre Therapeutics.

GNI has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).
• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Gyre Therapeutics

• Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company’s Nominees on the WHITE Proxy Card | Catalyst Biosciences
• Catalyst Biosciences Announces Support from Largest Single Stockholder | Catalyst Biosciences
• Catalyst Biosciences Publishes New Investor Presentation | Catalyst Biosciences
• Catalyst Biosciences Sends Letter to Stockholders | Catalyst Biosciences
• Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling | Catalyst Biosciences
• Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders | Catalyst Biosciences
• Catalyst Biosciences Sells Complement Portfolio for $60 Million | Catalyst Biosciences
• Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results | Catalyst Biosciences
• Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update | Catalyst Biosciences
• Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology | Catalyst Biosciences
• View more press releases Close

Social media about Gyre Therapeutics

• Gyre Therapeutics on Wikipedia, Google News & Yahoo Finance
• Gyre Therapeutics on LinkedIn, X (Twitter) & YouTube